Specialty vs Generalist Brokers for Life Sciences

Most life sciences companies start with a generalist broker. There is nothing inherently wrong with that at the earliest stages, when the program is a basic general liability and workers’ compensation placement and the regulatory exposure is light. The structural problem arises when the company moves into substantive regulatory territory and the generalist broker stays on the account. The exposure has changed, but the broker’s depth has not.

This piece is direct on the failure modes generalist brokers exhibit in life sciences placements, what specialty knowledge actually looks like in practice, and the specific questions a buyer can ask broker candidates to evaluate fit. The goal is to give founders, CFOs, and operating leaders a working framework for the broker selection conversation, which is one of the most consequential decisions in the insurance program.

Where Generalists Fail

Five failure modes recur in life sciences placements where a generalist broker is the broker of record.

Misreading FDA Frameworks

A generalist broker without medical device or pharmaceutical experience tends to treat FDA regulation as background noise rather than a structural input to coverage design. The practical effects show up across multiple coverage lines.

Products liability is the most common failure point. A generalist will place a generic products liability policy and call it done. A specialty broker reading the same risk knows the placement needs to anticipate the device class, the clearance pathway, the indication, the IFU language, the post-market surveillance posture, and the recall trigger interaction. A 510(k)-cleared device with a narrow indication is a different placement from a De Novo product or a Class III PMA device, and the underwriting questions differ.

Tech E&O for SaMD is another failure point. The generalist sees software and reaches for a generic tech E&O product. The specialty broker reads the same risk and knows the software functions as a medical device, that products liability exposure runs in parallel, and that the policy wording needs to address clinical decision impact. For the substantive framing on SaMD specifically, see What insurance does an FDA-regulated SaMD company need?.

Recall coverage is a third failure point. Generalists often miss recall coverage entirely or place it as a sub-limit inside products liability rather than as a distinct line. For the structural framing on recall, see Recall Coverage for Medical Device Manufacturers.

Missing the HIPAA Architecture

For digital health and clinical lab placements, the HIPAA framework determines the cyber coverage structure. Generalist cyber treats data as data. Specialty cyber for HIPAA-regulated companies distinguishes covered entity from business associate, anticipates BAA contractual liability, and calibrates regulatory defense limits to OCR enforcement posture. The OCR Risk Analysis Initiative has produced more than fifty enforcement actions through 2026, and the regulatory defense exposure runs accordingly. A generalist cyber placement that caps regulatory defense at pre-2024 levels structurally underinsures a company under active enforcement risk.

The proposed Security Rule update issued as an NPRM in December 2024 would, if finalized, require mandatory MFA, universal ePHI encryption, and annual risk analysis. Specialty cyber underwriters writing the HIPAA segment already treat these controls as binding thresholds. Generalist brokers reading the same risks tend to underprepare clients for the documentation expectations because the specific HIPAA enforcement context is not part of their daily practice.

Mishandling Carrier Appointments

Specialty life sciences and HIPAA-regulated cyber are written by a narrow group of markets. The appointment panel for these markets is smaller than the general commercial appointment panel. A generalist broker without specialty appointments is placing through a wholesale relationship at best, and frequently through a market that does not actually have appetite for the specific exposure.

The practical effect is two-fold. First, the placement options are narrower than the buyer realizes. The broker is offering what the broker can access, not what the market actually writes. Second, the underwriting conversation is mediated by an intermediary who may not be fluent in the substantive risk, which produces miscommunication between the buyer and the underwriter.

A specialty broker carries direct appointments with the markets that write the segment. The placement runs broker-to-underwriter rather than broker-to-wholesale-to-underwriter, and the conversation reflects substantive risk knowledge.

Inadequate Diligence Preparation

Investor diligence consistently flags insurance gaps in life sciences targets. A broker who has not worked the investor diligence side of a placement underestimates what counsel actually checks and where the typical gaps surface. For the structural framing on what investors look for, see What investors look for in a life sciences company’s insurance program during due diligence.

The failure mode is a placement that satisfies the company’s operational needs but does not satisfy investor counsel at the next round. Side A structure, named insured accuracy, effective date alignment with close milestones, BAA inventory adequacy, and claims history disclosure are all areas where generalist placements produce diligence flags. Specialty brokers anticipate these from the initial placement structure.

Underestimating Specialty Coverage Lines

Several coverage lines that are central to life sciences placements rarely appear in generalist programs.

Clinical trial liability as a distinct placement, with sponsor and CRO considerations and site requirements.

Crime coverage sized to the actual exposure rather than to a generic small-business standard.

International coverage for companies operating across the US, EU, and other jurisdictions with different regulatory frameworks.

Product recall expense as a distinct policy with adequate sub-limits for business interruption and brand rehabilitation.

Pollution liability for laboratory operations involving hazardous materials.

A generalist program frequently lacks one or more of these lines outright, or carries them as token sub-limits within an inadequate parent policy.

What Specialty Knowledge Looks Like

The shorthand for whether a broker has substantive life sciences depth is whether they can discuss the regulatory frameworks in the language the regulators and the carriers use.

A specialty broker discussing a SaMD placement knows what a 510(k) Special is, what a De Novo decision means, what a PCCP is, and how the Section 524B cybersecurity framework interacts with cyber coverage. They know that the QMSR took effect February 2, 2026, and what that did to the documentation expected at audit. They know that adverse event reporting under 21 CFR Part 803 carries 30-day and 5-day reporting timelines and how that affects claim notice provisions in policies.

A specialty broker discussing a HIPAA-regulated cyber placement knows the covered entity and business associate distinction in 45 CFR 160.103, can explain why the OCR Risk Analysis Initiative changed the documentation expected at OCR inquiry, and can discuss the structural difference between regulatory defense coverage that anticipates OCR posture versus generic data breach coverage.

A specialty broker discussing a clinical lab placement knows what high-complexity CLIA certification requires, can discuss the LIS architecture and the BAA flow-down to reference labs, and can explain why business interruption sub-limits in a generic cyber policy are inadequate for a high-throughput testing operation.

The test is not whether the broker has heard of these terms. The test is whether the broker uses them naturally and connects them to specific placement decisions.

Questions Buyers Should Ask

Five questions surface the specialty knowledge gap quickly.

“Which carriers do you have direct appointments with for [specific coverage line]?” Specialty placements run through direct appointments. A broker who cannot name specific markets they place with for the segment is working through wholesale relationships and intermediaries.

“Walk me through how the [FDA framework, HIPAA framework, CLIA framework] affects the coverage structure.” A specialty broker can explain the structural interaction. A generalist will reach for general statements about regulation and risk.

“What does your typical placement look like for a company at our stage and segment?” The answer should include specific structural choices: Side A structure, BI sub-limits, regulatory defense sub-limits, and the placement timeline.

“Have you placed coverage for a company that experienced [a 483, an OCR investigation, a recall, a clinical trial adverse event]?” Direct claim and regulatory event experience is the most valuable broker asset. Brokers without it lean on theoretical knowledge.

“What gaps do you typically find when you review an incoming program for a company in our segment?” A specialty broker has a short, specific answer based on pattern recognition. A generalist will offer general statements.

The Cost of the Wrong Broker

The cost of working with a generalist on a substantive life sciences placement is rarely visible in the year of the placement. It surfaces later, in one of three ways.

At investor diligence. Counsel reviews the program and flags structural gaps. The remediation is placed under deadline pressure with narrowed market options. The company is on its back foot during the diligence conversation that should have been an asset.

At claim. A claim arises and the policy responds in ways the company did not anticipate. Coverage triggers, exclusions, or sub-limits that the broker did not flag at placement become operational issues during the claim. The cost of the misalignment is the difference between the claim payment received and the claim payment a properly structured program would have produced.

At regulatory action. An OCR investigation, a 483, a Warning Letter, or a state agency inquiry arrives and the regulatory defense coverage proves inadequate for the actual enforcement posture. The company pays out of pocket for defense costs that should have flowed through the policy.

The dollar magnitude of these costs is rarely small. The structural decisions made at placement compound over the policy life, and the cost of misalignment shows up at the wrong moment.

How the Broker Conversation Should Unfold

A specialty placement conversation has a recognizable structure.

The broker asks for the company’s regulatory profile early: FDA correspondence history, HIPAA exposure, CLIA status, clinical trial activity, supply chain structure. The questions are specific because the broker is mapping the exposure surface, not running a generic intake.

The broker brings carrier-specific appetite information into the conversation. They know which markets are open to the company’s profile, which are restrictive, and which are uninterested. This information is current and based on direct market relationships.

The broker proposes a placement structure before talking about premium. The structure addresses the substantive exposure surface. Premium is a function of structure, not a primary input to it.

The broker anticipates investor diligence and structures the program to satisfy it from initial placement. This is a future-state consideration but a current-state design input.

The broker stays close to the regulatory environment. They know what changed at the most recent OCR newsletter, what the FDA guidance pipeline looks like, and how the carrier appetite is responding to regulatory shifts.

A Note on Placement

MedTech Coverage operates as a specialty practice for life sciences and HIPAA-regulated companies. Coverage is placed through Tower Street Insurance’s appointments with the specialty markets that write the medical device, clinical laboratory, and digital health segments. The placement workflow begins with the regulatory profile and operational reality of the company, not with a premium quote.

If a current program needs to be evaluated for specialty fit, or a new placement is being scoped, a structured coverage review produces a working document mapped to the company’s actual regulatory posture and exposure surface.